menu
    • menu
    [{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"CAR20.19.22 Cell","moa":"CD20\/CD19\/CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Miltenyi Biotec \/ Miltenyi Biotec","highestDevelopmentStatusID":"6","companyTruncated":"Miltenyi Biotec \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Miltenyi Biotec","highestDevelopmentStatusID":"6","companyTruncated":"Miltenyi Biotec \/ Miltenyi Biotec"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"CBE-101","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Cell BioEngines","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Cell BioEngines"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Syena","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SY-001","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Syena","highestDevelopmentStatusID":"5","companyTruncated":"Miltenyi Biotec \/ Syena"},{"orgOrder":0,"company":"Miltenyi Biotec","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"TCR\u03b1\u03b2+\/CD45RA","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Miltenyi Biotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Miltenyi Biotec \/ Miltenyi Biotec","highestDevelopmentStatusID":"1","companyTruncated":"Miltenyi Biotec \/ Miltenyi Biotec"}]

    Find Clinical Drug Pipeline Developments & Deals by Miltenyi Biotec

    Menu

    Miltenyi Biotec

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCRαβ+/CD45RA

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Ruijin Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            T-Cell-Depleted Haplo Transplant + CAR-T & Memory T Cells in Acute Leukemia

                            Details : TCRαβ+/CD45RA is a Cell and Gene therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Leukemia.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 28, 2025

                            Lead Product(s) : TCRαβ+/CD45RA

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Ruijin Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBE-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Cell BioEngines

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical ...

                            Details : Under the agreement, Miltenyi will develop and manufacture Cell BioEngines' expanded hematopoietic stem cell transplantation (HSCT) product, CBE-101, for clinical use in hematology-oncology.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 29, 2023

                            Lead Product(s) : CBE-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Cell BioEngines

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SY-001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Syena

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Syena and Miltenyi Biotec Enter into Exclusive Licensing and GMP Manufacturing Agreement for PRAME TCR-NK Cell...

                            Details : Under the agreement, Syena will support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy, SY-001, targeting the tumor-associated neoantigen, PRAME.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : SY-001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Syena

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Hospital Israelita Albert Einstein

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor ...

                            Details : Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Hospital Israelita Albert Einstein

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed

                            Miltenyi Biotec

                            Germany arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR20.19.22 Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Medical College of Wisconsin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

                            Details : CAR20.19.22 Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 26, 2021

                            Lead Product(s) : CAR20.19.22 Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Medical College of Wisconsin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth